EUCTR2017-002088-16-IT进行中（未招募）1 期
Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma - CD19-CAR01
Bambino Gesù Children's Hospital0 个研究点目标入组 32 人开始时间: 2018年1月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Procurement eligibility Inclusion Criteria
- •The patient must meet the following eligibility inclusion criteria at the time of procurement.
- •1.Diagnosis of CD19 expressing B acute lymphoblastic leukemia (ALL) or Non-Hodgkin Lymphoma (NHL) with BM involvement and one of the following:
- •a.Patients in 2nd or subsequent relapse, after at least one standard frontline chemotherapy and one salvage regimen, with BM involvement
- •b.Relapse after allogeneic HSCT, if at least 100 days post-transplant, if there is no evidence of active GVHD and if the patient is no longer taking immunosuppressive agents for at least 30 days prior to enrollment
- •c.MRD > 0.1% after either reinduction therapy or any course of consolidation for relapsed ALL
- •2.Age: 6 months – 25 years.
- •3.Adequate venous access for apheresis or eligible for appropriate catheter placement, and no other contraindications for leukapheresis
- •4.Voluntary informed consent is given. For subjects < 18 year-old their legal guardian must give informed consent. Pediatric subjects will be included in age-appropriate discussion and verbal assent will be obtained for those greater than or equal to 12 years of age, when appropriate.
- •5.Clinical performance status: Patients > 16 years of age: Karnofsky greater than or equal to 60%; Patients < 16 years of age: Lansky scale greater than or equal to 60%.
- •Treatment eligibility Patient Inclusion Criteria
- •The patient must meet the following eligibility inclusion criteria to be enrolled to receive treatment.
- •1.Male and female subjects with CD19 expressing B-cell acute lymphoblastic leukemia (ALL) or Non-Hodgkin Lymphoma (NHL) with BM involvement and one of the following:
- •i.Patients in 2nd or subsequent relapse, after at least one standard frontline chemotherapy and one salvage regimen, with BM involvement
- •ii.Relapse after allogeneic HSCT, if at least 100 days post-transplant, if there is no evidence of active GVHD and if the patient is no longer taking immunosuppressive agents for at least 30 days prior to enrollment
- •iii.MRD > 0.1% after either reinduction therapy or any course of consolidation for relapsed ALL
- •2.Measurable or evaluable disease at the time of enrollment, which may include any evidence of disease, including MRD detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.
- •3.Age: 6 months – 25 years.
- •4.Voluntary informed consent is given. For subjects < 18 year-old their legal guardian must give informed consent. Pediatric subjects will be included in age-appropriate discussion and verbal assent will be obtained for those greater than or equal to 12 years of age, when appropriate.
- •5.Clinical performance status: Patients > 16 years of age: Karnofsky greater than or equal to 60%; Patients < 16 years of age: Lansky scale greater than or equal to 60%.
- •6.Patients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimen.
- •7.Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 28
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Procurement eligibility Exclusion Criteria
- •1.Severe, uncontrolled active intercurrent infections
- •2.HIV, or active HCV and/or HBV infection
- •3.Concurrent or recent prior therapies, before apheresis:
- •a.Systemic steroids (at a dose equivalent to or greater 2 mg/kg prednisone) in the 2 weeks before apheresis collection. Recent or current use of inhaled/topical/non-absorbable steroids is not exclusionary.
- •b.Systemic chemotherapy in the 3 weeks preceding apheresis collection.
- •c.Anti-thymocyte globulin (ATG) or Alemtuzumab (Campath®) in the 4 weeks preceding apheresis collection.
- •d.Immunosuppressive agents in the 2 weeks preceding apheresis collection.
- •e.Radiation therapy must have been completed at least 3 weeks prior to apheresis.
- •f.Other anti-neoplastic investigational agents currently administered or within 30 days prior to apheresis (i.e. start of protocol therapy);
- •g.Exceptions:
- •a.There is no time restriction in regard to prior intrathecal chemotherapy, provided that there is complete recovery from any acute toxic effects of such;
- •b.Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study provided they meet all other eligibility criteria;
- •h.Subjects receiving steroid therapy at physiologic replacement doses only are allowed provided there has been no increase in dose for at least 2 weeks prior to starting apheresis.
- •Treatment eligibility Patient Exclusion criteria
- •1.Pregnant or lactating women
- •2.Severe, uncontrolled active intercurrent infections
- •3.HIV, or active HCV and/or HBV infection
- •4.Life-expectancy < 6 weeks
- •5.Hepatic function: Inadequate liver function defined as total bilirubin > 4x upper limit of normal (ULN) or transaminase (ALT and AST) > 6 x ULN
- •6.Renal function: serum creatinine > 3x ULN for age.
- •7.Blood oxygen saturation < 90%.
- •8.Cardiac function: Left ventricular ejection fraction lower than 45% by ECHO.
- •9.Congestive heart failure, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject.
- •10.BM blasts > 50% pre-infusion.
- •11.Hyperleukocytosis (greater than or equal to 20,000 blasts/microliter) or rapidly progressive disease that in the evaluation of the investigator would compromise ability to complete study therapy
- •12.Active CNS disease as documented by the presence of blasts in the CSF or by MRI. This criterion could be revised once that, after the phase I portion of the study, absence of life-threatening (i.e. grade IV) neurological toxicity will be documented.
- •13.Presence of active, grade 2-4 acute or extensive chronic GvHD
- •14.Recurrent or refractory ALL with testicular involvement
- •15.Concurrent or recent prior therapies, before infusion:
- •i.Systemic steroids (at a dose > 2 mg/kg prednisone) in the 2 weeks before infusion. Recent or current use of inhaled/topical/non-absorbable steroids is not exclusionary.
- •ii.Systemic chemotherapy in the 2 weeks preceding infusion.
- •iii.Anti-thymocyte globulin (ATG) or Alemtuzumab (Campath®) in the 4 weeks preceding infusion.
- •iv.Immunosuppressive agents in the 2 weeks preceding infusion.
- •v.Radiation therapy must have been completed at least 3 weeks prior to enrollment.
- •vi.Other anti-neoplastic investigational agents currently administered or within 30 days prior to infusion (i.e. start of proto
研究者
相似试验
进行中（未招募）
1 期
CD19-CAR_Lenti in pediatric patients affected by relapsed/refractory B-ALL or aggressive B-NHEUCTR2020-003452-32-ITIRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA32
招募中
1 期
Safety of Immune Cells for Patients with Relapsed Leukaemia or Lymphoma after Bone Marrow TransplantACTRN12617001579381Western Sydney Local Health District, Westmead Hospital20
尚未招募
1 期
Safety of Immune Cells for Patients with Relapsed Leukaemia or Lymphoma after ChemotherapyAcute Lymphoblastic LeukaemiaChronic Lymphocytic LeukaemiaNon-Hodgkins LymphomaCancer - Leukaemia - Acute leukaemiaCancer - Leukaemia - Chronic leukaemiaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaACTRN12619000079145Western Sydney Local Health District, Westmead Hospital20
尚未招募
不适用
A pilot study of AT101 in anti-CD19 CAR T therapy-exposed patients with relapsed or refractory diffuse large B cell lymphomaNeoplasmsKCT0009570Asan Medical Center10
Unknown
1 期
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic LeukemiaB Cell LymphomaB-cell Acute Lymphoblastic LeukemiaNCT04289220Yan'an Affiliated Hospital of Kunming Medical University10